Publicatiedatum 01-11-2019 | 13:01
Good Practice on the assessment of GMO related aspects in the context of clinical trials with AAV (Adeno-Associated Virus) clinical vectors
See also: https://ec.europa.eu/health/human-use/advanced-therapies_en